Stock Pick – Page 48 – Curated Stock Market News

Stock market news live updates: Stocks post worst drop in seven sessions; Grubhub spikes on takeover reports

Stocks erased earlier gains and traded lower Tuesday, as investors continued to eye states’ reopening plans and mulled recent corporate earnings results. Market participants also eyed the start of the Federal Reserve’s program to purchase corporate debt exchange-traded funds, which kicks off Tuesday.

from Yahoo Finance https://ift.tt/3cpZMw2

12 May 2020

Fed begins purchasing corporate-bond ETFs

from Yahoo Finance https://ift.tt/3br1Fr1

12 May 2020

Is Applied Materials, Inc. (NASDAQ:AMAT) Potentially Undervalued?

Today we're going to take a look at the well-established Applied Materials, Inc. (NASDAQ:AMAT). The company's stock…

from Yahoo Finance https://ift.tt/2YW9WRe

12 May 2020

Stock market news live updates: Stocks post worst drop in seven sessions; Grubhub spikes on takeover reports

Fed begins purchasing corporate-bond ETFs

Is Applied Materials, Inc. (NASDAQ:AMAT) Potentially Undervalued?

Up 67%! Is it too late to buy the rally in Guzman Y Gomez shares now?

2 ASX energy companies Macquarie says can jump more than 37%

Sell alert! Why this expert is calling time on Woolworths and CBA shares

Codan vs Droneshield shares: Which is the better buy?

Worried about a downturn? 3 ASX shares and 3 ETFs built to weather it

Brokers tip these 3 ASX shares to climb between 50% and 122% in the next 12 months

MarineMax, Inc.’s (NYSE:HZO) Share Price Not Quite Adding Up

Milestone Pharmaceuticals Announces $25 Million Private Placement

There is a ‘ridiculous amount of speculation’ over coronavirus vaccine stocks: biotech analyst

Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans

The Latest

MarineMax, Inc.’s (NYSE:HZO) Share Price Not Quite Adding Up

Milestone Pharmaceuticals Announces $25 Million Private Placement

There is a ‘ridiculous amount of speculation’ over coronavirus vaccine stocks: biotech analyst

Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans